questions for the first time. The aim of the present study was to test the interrater reliability of PANSS-6 ratings obtained using the SNAPSI. Methods: The team of raters (five medical doctors and two psychologists) attended training sessions prior to the inter-rater reliability test. At the training sessions one rater interviewed a patient with schizophrenia using the SNAPSI, while all raters conducted PANSS-6 ratings independently. After each interview the PANSS-6 ratings were discussed until an agreement was reached. Each rater participated in at least six SNAPSI/PANSS-6 training ratings. For the inter-rater reliability test, a total of 12 patients with a primary diagnosis of schizophrenia, currently undergoing in-or outpatient treatment at the Department for Psychosis, Aarhus University Hospital -Denmark, will be recruited. The team of raters will perform a total of at least 50 PANSS-6 ratings via SNAPSI. All raters will conduct the SNAPSI at least once. As a measure of inter-rater reliability, we will calculate the Intraclass Correlation Coefficient based on the 50 PANSS-6 ratings.
S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS -RESULTS FROM AN EXPLORATORY RE-ANALYSIS
Background: Repetitive transcranial magnetic stimulation (rTMS) applied to the left frontal lobe is discussed to be a promising add-on treatment for negative symptoms in schizophrenia. The Positive and Negative Syndrome Scale (PANSS) has been used as outcome parameter in several previous rTMS trials, but studies focusing on PANSS factor analyses are lacking. For this purpose, we used the available PANSS data of the 'rTMS for the Treatment of Negative Symptoms in Schizophrenia' (RESIS) trial to calculate different literature-based PANSS factors and to re-evaluate the impact of rTMS on negative symptoms in this trial.
Methods:
In an exploratory re-analysis of published data from the RESIS study (Wobrock et al. 2015) , we tested the impact of rTMS applied to the left dorsolateral prefrontal cortex on two PANSS factors for negative symptoms in psychotic disorders as well as on a PANSS five-factor consensus model intending to show that active rTMS treatment improves PANSS negative symptom subscores. Results: In accordance to the original analysis, all PANSS factors showed an improvement over time in the active and, to a considerable extent, also in the sham rTMS group. However, comparing the data before and directly after the rTMS intervention, the PANSS excitement factor improved in the active rTMS group significantly more than in the sham group, but this finding did not persist if follow-up data were taken into account. These additional analyses extend the previously reported RESIS trial results showing unspecific improvements in the PANSS positive subscale in the active rTMS group. Our PANSS factor-based approach to investigate the impact of prefrontal rTMS on different negative symptom domains confirmed no overall beneficial effect of the active compared to sham rTMS. Discussion: This secondary analysis of the RESIS trials has several limitations. First of all, the analysis of the primary endpoint was negative [24] and all subsequent secondary analyses showing a positive effect of the intervention (here: change in PANSS excitement factor) are of limited statistical power and therefore subject to uncertainty. On the other hand, our analyses confirm the negative finding of the original publication extends this finding to a broader negative symptom definition. Moreover, the new analysis provides a possible, but hypothetical explanation for the previously described effect of active rTMS on PANSS positive subscale. Of course, many other PANSS factor models are available and in pharmacological research the Marder factors [23, 35] Background: Motivation deficits are among the strongest determinants of reduced functioning and quality of life in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits because they can provide frequent cues and reinforcements to support goaldirected behavior in daily life. The objective of this study is to assess the initial feasibility/acceptability and effectiveness of Mobile Enhancement of Motivation in Schizophrenia (MEMS), a personalized mobile text message intervention, compared to a goal-setting alone intervention. Methods: Fifty-six participants with a schizophrenia-spectrum disorder have been enrolled in this ongoing controlled pilot study. Twenty-seven participants have been randomized to MEMS, while 29 participants have been randomized to the goal-setting alone condition. Participants in both groups set individualized recovery goals to complete over an 8-week period. Those in the MEMS group also receive three sets of personalized, interactive text messages each weekday to reinforce and cue goal completion. Blinded assessments are conducted before and after the 8-week period and include validated measures of motivation, quality of life, and functioning. Goal attainment and self-reported satisfaction with MEMS are also assessed. Results: To date, 36 participants (n = 18 in each group) have completed both baseline and follow-up assessments. Initial results suggest that relative to the goal-setting alone group, the MEMS group demonstrated significantly greater improvements in clinician-rated motivation (F(1, 33) = 7.14, p = .01; between-group d = .89). Specifically, the MEMS group demonstrated significantly higher clinician-rated motivation after 8 weeks (withingroup d = .62), while clinician-rated motivation remained the same in the goal-setting alone group (within-group d = -.02). Across both groups, participants also significantly improved on clinician-rated functioning over time (t(35) = -2.56, p = .02, d = .43), but there was no difference between the two groups (F(1, 33) = .01, p = .94; between-group d = .03). No improvement on self-reported quality of life was observed in either group or across the full sample. The MEMS group reported strong satisfaction with the text-messages. Recruitment has been completed, and analyses from the full sample will be ready to present at the meeting. Discussion: Initial results indicate that MEMS is acceptable and may successfully improve motivation in people with schizophrenia-spectrum disorders. However, additional analyses with the full sample are needed to more rigorously test the feasibility and effectiveness of MEMS. , 2011) . As the smartphone user population continues to increase, the effectiveness of CR based on mobile devices have started to be studied. While CR is effective in improving cognitive deficit, treatment adherence and engagement of participants in the real world setting is known to be poor compared to laboratory setting. Thus, in the current randomized controlled study, we aimed to investigate whether motivational intervention would enhance motivation, treatment adherence and neurocognitive function of individuals with schizophrenia. Methods: All subjects participated in a group-based CR using mobile application (mCR) twice a week for five weeks, and were given opportunity to practice voluntarily outside the treatment sessions. While CR only group participated in usual CR with Q&A sessions, experimental group participated CR sessions integrated with motivational intervention. For motivational enhancement (ME), we employed principles (e.g., goal setting, linking of CR with life goals, etc) of the bridging group (Medalia, Revheim, & Herlands, 2009 ) along with key aspects of motivational interviewing (e.g., open end questions, affirmation, reflect, and summary). We hypothesized that compared to CR only group, CR+ME group would show higher levels of intrinsic motivation, attendance rate and extra voluntary training hours, and greater improvement in cognitive functions.
S51. MOTIVATIONAL ENHANCEMENT

Results:
We are undergoing the current project, and a total of 14 participants were randomly assigned to either CR+ME (n=8) or CR only (n=5). Among 14 participants, two participants dropped out (n=1 experimental group and n=1 control group). Independent sample t-test were used to compare scores of demographics and clinical characteristics between groups, and no differences were found except for the PANSS excitement subscale (t = 2.91, P < .05) at the time of pre-treatment. Due to a small sample, we conducted paired sample t-tests to examine whether there was a significant difference between the pre and post-test for two groups, respectively. The paired t-test revealed improvements in coding, TMT-B, logical memory I and K-AVLT immediate recall performances of CR+ME (t=-2.92, p < .01; t=-3.65, p < .05; t=-3.20, p < .05; t=-2.89, p < .05), but not CR only. In addition, there were pre and post-treatment differences in motivation variables (MSQ) for CR+ME.
Comparing task related motivational level of first session to the final 10th session, CR+ME showed increased identified regulation(IR) score of MSQ and decreased external regulation(ER) score (IR=22.3(3.2), 23.5(3.7); ER= 10.67 (3.88), 6.67 (3.08)). Discussion: We conclude that ME is promising to further enhance neurocognitive and motivational outcomes of mCR. The data collection process is expected to be completed in late January 2018, and the results will be accordingly updated by the time of presentation at SIRS 2018. Limitations and future directions will be discussed. 
S52. WORKING MECHANISMS OF VIRTUAL
Zanjan University of Medical Sciences
Background: Cognitive impairment is the most important feature of schizophrenia that leads to severe social and functional disability. Improving neurocognitive physiopathologic aspect of schizophrenia is a current challenge to identify the pathway to develop goal directed clinical interventions in practice. In the current study we investigated the effect of raloxifine as a selective estrogen modulator and isradipine as a voltage gated L type calcium channel blocker on the enhancement of schizophrenic patients' cognitive deficits. Methods: We designed a double blind randomized, parallel, placebo controlled clinical trials. 60 patients with schizophrenia randomized in 3 specific groups. The first group received isradipine 5 mg, the second raloxifine 60 mg and the third placebo for 6 consequent weeks, in the same shape capsules, 2 times a day, alongside treatment with the conventional antipsychotics. The initial and final lab tests, ECG, as well as cognitive tests in specific domains such as attention, processing speed, executive function and verbal memory were carried out. Results: Our findings, revealed a remarkable association between adjunctive treatment of raloxifine in verbal memory deficits. moreover, isradipine treatment indicated significant improvement relative to placebo in verbal memory as well as attention dysfunction in some variables of the Stroop test. However, no effect was observed in processing speed and executive function deficits. Discussion: The study provides the first evidence to our knowledge, which isradipine as a novel therapy was associated with improvement in verbal
